The pharmacokinetic characteristics of cefonicid, a highly protein-bound expanded-spectrum cephalosporin, were examined in six noninfected, clinically stable patients undergoing continuous ambulatory peritoneal dialysis. After a 1.0-g intravenous dose of cefonicid, the mean concentrations in serum were 105 + 25 and 35.6 ± 14.4 ,ug/ml at 3 and 72 h, respectively. Despite a prolonged half-life in serum of 49.7 ± 18 h, the penetration into peritoneal fluid was low. The average concentration in dialysate over the 72-h study period was 2.7 ,Ig/ml.
Bacterial peritonitis predominantly caused by staphylococcal species is a frequent complication of continuous ambulatory peritoneal dialysis (CAPD). Cephalosporins are commonly prescribed for the treatment of this complication. Antibiotics which can be administered on an infrequent basis are desirable to avoid hospitalization and simplify the treatment regimen for the convenience of the patient. In addition, an antibiotic which does not require administration in every dialysis exchange would decrease potential contamination caused by repeated admixture with dialysate fluid (11) .
Cefonicid is a long-acting cephalosporin with a half-life in serum of 3.5 to 4.5 h in patients with normal renal function (4, 8) . The half-life is further prolonged as creatinine clearance (CL) declines and has been noted to be as long as 70 h when creatinine CL is less than 5 ml/min (3). The present study was conducted to examine the pharmacokinetic characteristics of cefonicid in CAPD patients and to evaluate its potential for convenient intermittent intravenous therapy for CAPD-related peritonitis.
MATERIALS AND METHODS
Six stable CAPD patients with no clinical signs or symptoms of peritonitis were admitted to the study after informed consent was obtained. Patients were excluded if they had previous beta-lactam allergy, antibiotic therapy within the past 2 weeks, severe cardiac (clinical congestive failure) or hepatic (twice normal serum levels of alanine transferase, aspartate aminotransferase, or both) dysfunction, or abnormal coagulation (prothrombin time or partial thromboplastin time of 5 s greater than control) parameters.
An indwelling venous catheter was placed in the arm contralateral to the infusion site, and a 1.0-g dose of cefonicid was administered over 8 min. Blood samples were obtained at 0, 3, 6 (end of first dialysis period), 9 , 12 (end of second dwell period), 24, 48, and 72 h. CAPD was continued throughout the study period with q4h to q8h exchanges based on individual requirements. All dialysate drainage was measured, and a sample was saved. Blood samples were allowed to clot, and then serum was obtained by centrifugation. Serum and dialysate samples were stored at -30°C until assayed.
Analytical-grade cefonicid (Smith Kline & French Laboratories, Philadelphia, Pa.) was measured by highperformance liquid chromatography with a modification of a previously reported assay (6) . To 0.5 ml of sample (serum or dialysate), 0.2 ml of internal standard (cefazolin) and 1 ml of acetonitrile were added. The mixture was vortexed for 15 s, shaken for 5 min, and centrifuged (1,200 x g; 5 min). To the supernatant, 2 ml of methylene chloride was added, and the mixture was vortexed, shaken, and centrifuged as described above. A 20-pl quantity of the upper aqueous phase was injected onto a Varian Micropak C-18 column (Varian Laboratories, Walnut Creek, Calif.). A mobile phase of 1% methanol in 2 M sodium acetate (pH 5.2) was run at a flow rate of 1 ml/min, and cefonicid was monitored at 210 nm. The intraday and interday relative standard deviation was less than 7%.
Data on concentration in serum were entered into the LAGRAN program (9) to determine the area under the serum concentration versus time curve (AUC) and the serum concentration x time versus time curve (area under the moment curve, AUMC). Total CL, volume of distribution at steady-state (V,s), and the serum half-life (t1/2) were determined as follows: CL = dose/AUC0', Vs, = I CL, t1/2 = 0.693/A, where dose is the administered dose, f is the mean residence time (AUMC/AUC), and X is the slope of the elimination phase. In addition, the ratio of the amount of drug (XD) recovered via CAPD to the AUCO' was determined.
RESULTS
Cefonicid administration was well-tolerated by all of the CAPD patients. A representative serum and dialysate concentration versus time profile is illustrated in Fig. 1 Tables 1 and 2 , respectively.
DISCUSSION
In comparison with the t1/2 of 3 to 4 h in normal humans, the half-life of cefonicid in CAPD patients is markedly prolonged to 50 h. This value is similar but somewhat lower than that during hemodialysis, for which a t1/2 of 70 h has been reported (3). The major factor which prolongs the cefonicid t1/2 is the lack of a renal excretory route, upon which this drug is heavily dependent for elimination. Serum CL values of 25 ml/min in healthy subjects (3) far exceed the low values found during CAPD in the present study (2.6 ml/min) and during hemodialysis (1.9 ml/min) (3) . The volume of distribution of cefonicid in CAPD patients (0.14 liter/kg) is similar to that seen in hemodialysis patients, chronic renal failure, and normal humans (3) . Therefore, it is apparent that the prolonged serum t1/2 is dtie to decreased CL and not to changes in distribution volume.
Despite the prolonged serum t1/2 and the resultant elevation of concentrations in serum, concentrations in dialysate were variable and generally low among the study patients. The variability found for peritoneal drug concentrations is consistent with the results of other studies that have found a wide range of tissue-to-serum ratios in bone, uterine tissue, gallbladder, wounds, pus, pleural fluid, and breast milk (5) . The cotncentrations of cefonicid in peritoneal fluid, however, are lower than those reported in other tissue compartments. This finding may reflect the more complex nature of the peritoneai membrane and the numerous factors which affect solute diffusion from serum into dialysate (7). Although not studied in renal failure patients, the high degree of serum protein binding of cefonicid in normal serum (98%) is a prime factor which may contribute to slower diffusion into dialysate (2) . The low concentrations in dialysate are of some concern, in that the MIC for 50% of Staphylococcus aureus strains tested ranges from 2 to 4 jxg/ml and that for 50% of Staphylococcus epidermidis strains tested ranges from 4 to 8 p.g/ml (1) . Although the significance of achieving concentrations in dialysate above the MIC for a specific pathogen remains unclear, many CAPD centers advocate the continuous intraperitoneal administration of antibiotics to overcome subtherapeutic concentrations in dialysate (10) . More recently, the need for continuously adding cephalosporin antibiotics to dialysate has been questioned and an alternative treatment regimen with a single daily intraperitoneal dose has been suggested (11). In addition, antibiotic which is present in dialysate is primarily unbound to protein (5a). 
